Skip to main content
. 2015 Mar 18;10(3):e0118434. doi: 10.1371/journal.pone.0118434

Fig 4. Immune components required for post-exposure VLP protection.

Fig 4

(A) Various knockout mice were infected with EBOV and treated with VLPs 24 hours later. n = 10 (n = 20 for perforin and no VLP), 2 separate experiments. Nineteen of out 20 VLP treated control WT mice survived infection. (B) Wild-type mice were depleted of various cell types using depleting antibody treatment, infected with EBOV, and treated with VLP 24 hours after infection. Additionally, isotype controls for each antibody type used were tested. n = 5 (n = 10 for anti-NK1.1). (C) Mice lacking IFN-gamma or TNF-alpha were infected with EBOV and treated with VLP 24 hours later. n = 10 for IFN-gamma KO, n = 5 for TNF-alpha KO, n = 4 for WT, n = 20 for WT no VLP. (D) Wild-type mice were depleted of cytokines using depleting antibody treatment, infected with EBOV, and treated with VLP 24 hours after infection. Additionally, isotype controls for each antibody type used were tested. n = 5 (n = 10 for anti-TNF-alpha).